|
UltraScreen™ is a new strategic and tactical
approach to drug discovery which results from integrating
comprehensive and simultaneous leading edge assays of sorted
homogeneous cell sub-populations as early as possible in the
discovery process.
Early interrogation of sorted target cells will
allow sub-population analysis and efficacy assessment to occur
at the beginning of the product development cycle, thereby
minimizing the risks associated with committing massive resources
to sub-optimal target compounds.
EpiSep™, the core of The UltraPlatform™
system, enables UltraScreen™ to be implemented as a
direct result of its unique ability to combine sorted homogenous
cell sub-population capture with leading edge cellular and
molecular assays in a cost effective, simultaneous, simple,
rugged and scalable-to-HTS format.
Beyond the Microtiter Plate to Sorted
Homogeneous Cell Sub-Population Assays Currently
high throughput screening is predominately performed on samples
derived from heterogeneous cell populations. A primary reason
for this limitation is the overdependence of the pharmaceutical
research community on microtiter plate platforms which are
inherently unsuited for the capture, sorting and assay of
targeted sub-populations of cells in a high throughput environment.
UltraScreen as implemented on The UltraPlatform™
goes beyond microtiter plates because:
- It is flexible enough
to handle homogeneous cell sub-population analysis in a
high throughput environment.
- It permits dual FISH/Immunofluorescence
analysis of sorted homogeneous target cell populations.
- It enables more rapid and flexible cell
engineering and expansion applications.
- It eliminates the need for slow and cumbersome
cell culture steps in many applications.
- It is a rapid, cost effective, less labor
intensive, and highly flexible approach to drug discovery
and research.
|
